FROM PATIENTS NEEDS TO THE IMPLEMENTATION OF NEW TREATMENTS
FAVORABLE RESEARCH ENVIRONMENT
As a recipient of multiple NIH/DOD funds and awards, we are given access to an incredible research lab with state-of-the-art equipment and tools that allow us to continue producing breakthroughs for urgent medical issues in today's well-defined market.
Our scientific heritage is grounded in pushing the boundaries of small molecule discovery biologics. For decades, our scientists have led the way in identifying the right chemical leads. Much of our biologics work focuses on specially defined or targeted populations, determined by the scientific pathway of the disease and mode of the small molecules.
Triple Negative Breast Cancer (TNBC) is being intensively studied throughout our lab. Our researchers are working to find better ways to prevent, detect, and improve the quality of life of BC patients and survivors. Cancer patients who currently have important unmet treatment needs may have the most to gain from the targeted drugs for TNBC treatment.
We have played to our strengths successfully bringing critical-stage capabilities to early drug discovery from target identification through IND submission. We also work collaboratively with our external partners to harness breakthrough technologies across the life-cycle of our medicines.